ATOSSA THERAPEUTICS, INC. Q2 2026: Net loss $(8.49M), EPS $(0.95) — 10-Q SummaryTradingView·Aug 7 at 12:41 PMATOS-0.40%
Atossa Therapeutics Q2 net loss widens to $18.1 million; reports no revenuePUBT·Aug 7 at 12:32 PMATOS-0.40%
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | ATOS Stock NewsStockTitan·Aug 7 at 04:45 AMATOS-0.40%
Atossa says novel endoxifen-related compounds show potent preclinical activity in ER-positive breast cancer modelsPUBT·Jul 28 at 12:30 PMATOS-0.40%
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers | ATOS Stock NewsStockTitan·Jul 21 at 04:30 AMATOS-0.40%
Atos Named ‘Best in Class’ in Multiple Categories Across the 2026 PAC RADAR Evaluation of SAP Service ProvidersGlobeNewswire·Jul 1 at 08:42 AMSAP
Atossa Therapeutics, Inc. (NASDAQ:ATOS): Are Analysts Optimistic?Simplywall·Jun 25 at 10:58 AMATOS-0.40%
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds | ATOS Stock NewsStockTitan·Jun 12 at 01:30 PMATOS-0.40%
